Global ED Treatment Market Research Report 2024
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Sildenafil
Tadalafil
Others
Segment by Application
Hospitals
Drugstores
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Eli Lilly
Pfizer
Bayer
BaiYunShan General Factory
S.K. Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
CSBIO.

Table of Content
1 ED Treatment Market Overview
1.1 Product Overview and Scope of ED Treatment
1.2 ED Treatment Segment by Type
1.2.1 Global ED Treatment Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Sildenafil
1.2.3 Tadalafil
1.2.4 Others
1.3 ED Treatment Segment by Application
1.3.1 ED Treatment Sales Comparison by Application: (2021-2027)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Other
1.4 Global ED Treatment Market Size Estimates and Forecasts
1.4.1 Global ED Treatment Revenue 2016-2027
1.4.2 Global ED Treatment Sales 2016-2027
1.4.3 ED Treatment Market Size by Region: 2016 Versus 2021 Versus 2027
2 ED Treatment Market Competition by Manufacturers
2.1 Global ED Treatment Sales Market Share by Manufacturers (2016-2021)
2.2 Global ED Treatment Revenue Market Share by Manufacturers (2016-2021)
2.3 Global ED Treatment Average Price by Manufacturers (2016-2021)
2.4 Manufacturers ED Treatment Manufacturing Sites, Area Served, Product Type
2.5 ED Treatment Market Competitive Situation and Trends
2.5.1 ED Treatment Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest ED Treatment Players Market Share by Revenue
2.5.3 Global ED Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 ED Treatment Retrospective Market Scenario by Region
3.1 Global ED Treatment Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global ED Treatment Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America ED Treatment Market Facts & Figures by Country
3.3.1 North America ED Treatment Sales by Country
3.3.2 North America ED Treatment Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe ED Treatment Market Facts & Figures by Country
3.4.1 Europe ED Treatment Sales by Country
3.4.2 Europe ED Treatment Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific ED Treatment Market Facts & Figures by Region
3.5.1 Asia Pacific ED Treatment Sales by Region
3.5.2 Asia Pacific ED Treatment Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America ED Treatment Market Facts & Figures by Country
3.6.1 Latin America ED Treatment Sales by Country
3.6.2 Latin America ED Treatment Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa ED Treatment Market Facts & Figures by Country
3.7.1 Middle East and Africa ED Treatment Sales by Country
3.7.2 Middle East and Africa ED Treatment Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global ED Treatment Historic Market Analysis by Type
4.1 Global ED Treatment Sales Market Share by Type (2016-2021)
4.2 Global ED Treatment Revenue Market Share by Type (2016-2021)
4.3 Global ED Treatment Price by Type (2016-2021)
5 Global ED Treatment Historic Market Analysis by Application
5.1 Global ED Treatment Sales Market Share by Application (2016-2021)
5.2 Global ED Treatment Revenue Market Share by Application (2016-2021)
5.3 Global ED Treatment Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Eli Lilly Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Pfizer Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Bayer Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 BaiYunShan General Factory
6.4.1 BaiYunShan General Factory Corporation Information
6.4.2 BaiYunShan General Factory Description and Business Overview
6.4.3 BaiYunShan General Factory ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.4.4 BaiYunShan General Factory Product Portfolio
6.4.5 BaiYunShan General Factory Recent Developments/Updates
6.5 S.K. Chemicals
6.5.1 S.K. Chemicals Corporation Information
6.5.2 S.K. Chemicals Description and Business Overview
6.5.3 S.K. Chemicals ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.5.4 S.K. Chemicals Product Portfolio
6.5.5 S.K. Chemicals Recent Developments/Updates
6.6 Teva Pharma
6.6.1 Teva Pharma Corporation Information
6.6.2 Teva Pharma Description and Business Overview
6.6.3 Teva Pharma ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Teva Pharma Product Portfolio
6.6.5 Teva Pharma Recent Developments/Updates
6.7 Dong-A ST
6.6.1 Dong-A ST Corporation Information
6.6.2 Dong-A ST Description and Business Overview
6.6.3 Dong-A ST ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Dong-A ST Product Portfolio
6.7.5 Dong-A ST Recent Developments/Updates
6.8 Metuchen Pharma
6.8.1 Metuchen Pharma Corporation Information
6.8.2 Metuchen Pharma Description and Business Overview
6.8.3 Metuchen Pharma ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Metuchen Pharma Product Portfolio
6.8.5 Metuchen Pharma Recent Developments/Updates
6.9 Seoul Pharma
6.9.1 Seoul Pharma Corporation Information
6.9.2 Seoul Pharma Description and Business Overview
6.9.3 Seoul Pharma ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Seoul Pharma Product Portfolio
6.9.5 Seoul Pharma Recent Developments/Updates
6.10 CSBIO.
6.10.1 CSBIO. Corporation Information
6.10.2 CSBIO. Description and Business Overview
6.10.3 CSBIO. ED Treatment Sales, Revenue and Gross Margin (2016-2021)
6.10.4 CSBIO. Product Portfolio
6.10.5 CSBIO. Recent Developments/Updates
7 ED Treatment Manufacturing Cost Analysis
7.1 ED Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of ED Treatment
7.4 ED Treatment Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 ED Treatment Distributors List
8.3 ED Treatment Customers
9 ED Treatment Market Dynamics
9.1 ED Treatment Industry Trends
9.2 ED Treatment Growth Drivers
9.3 ED Treatment Market Challenges
9.4 ED Treatment Market Restraints
10 Global Market Forecast
10.1 ED Treatment Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of ED Treatment by Type (2022-2027)
10.1.2 Global Forecasted Revenue of ED Treatment by Type (2022-2027)
10.2 ED Treatment Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of ED Treatment by Application (2022-2027)
10.2.2 Global Forecasted Revenue of ED Treatment by Application (2022-2027)
10.3 ED Treatment Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of ED Treatment by Region (2022-2027)
10.3.2 Global Forecasted Revenue of ED Treatment by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer